Related Articles
Chaperone protein P4HB predicts temozolomide response and prognosis in malignant glioma
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
Molecular characteristics of pediatric non-ependymal, non‑pilocytic gliomas associated with resistance to temozolomide
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review)
Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors